Rankings / Cognitive — Prescription Stimulants
Centanafadine
Cognitive · NDRI / triple reuptake inhibitor (non-stimulant ADHD)
Tier B+
Bottom line
Read Off Label grades Centanafadine as B+ (7.2/10) based on strong evidence, moderate benefit magnitude, and a low-med-risk safety profile.
Otsuka's bid for a non-stimulant 'next Adderall' — it hits the same dopamine/norepinephrine targets without being a scheduled drug.
Typical use: Oral; sustained-release formulation used in Phase 3 — Investigational.
What this is
Otsuka's bid for a non-stimulant 'next Adderall' — it hits the same dopamine/norepinephrine targets without being a scheduled drug. Backed by four pivotal Phase 3 trials across adults, adolescents and children (positive topline 2024-2025); 2026 post-hoc analyses (n=744 adults) showed gains in self-reported executive function and emotional dysregulation on top of core symptom control. FDA accepted the NDA with Priority Review (PDUFA July 24 2026). Would be the first new-mechanism non-stimulant ADHD drug in years. Industry-sponsored; peer-reviewed pivotal publications pending.
Mechanism
Serotonin-norepinephrine-dopamine triple reuptake inhibitor; raises synaptic dopamine and norepinephrine like a stimulant but without forcing their release, aiming for stimulant-level ADHD efficacy with lower abuse potential and a non-scheduled profile
Dose & route
Oral; sustained-release formulation used in Phase 3
Citations
- https://www.otsuka-us.com/news/otsuka-announces-fda-acceptance-and-priority-review-new-drug-application-centanafadine
- https://www.otsuka-us.com/news/otsuka-pharmaceutical-announces-positive-topline-results-two-pivotal-phase-3-trials
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does Centanafadine work?
- Read Off Label rates the evidence for Centanafadine as Strong and the benefit magnitude as moderate, producing an overall grade of B+ (7.2/10). Otsuka's bid for a non-stimulant 'next Adderall' — it hits the same dopamine/norepinephrine targets without being a scheduled drug.
- Is Centanafadine safe?
- Centanafadine has a low-med risk profile in published human data. Legal status: Investigational (FDA NDA accepted, Priority Review; PDUFA July 24 2026 — children/adolescents/adults). This is not medical advice — see the disclaimer.
- What is the typical dose for Centanafadine?
- Oral; sustained-release formulation used in Phase 3
- How does Centanafadine work?
- Serotonin-norepinephrine-dopamine triple reuptake inhibitor; raises synaptic dopamine and norepinephrine like a stimulant but without forcing their release, aiming for stimulant-level ADHD efficacy with lower abuse potential and a non-scheduled profile
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.